In re BioScrip, Inc. Securities Litigation

273 F. Supp. 3d 474
CourtDistrict Court, S.D. New York
DecidedJuly 26, 2017
Docket13-cv-6922 (AJN)
StatusPublished
Cited by5 cases

This text of 273 F. Supp. 3d 474 (In re BioScrip, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re BioScrip, Inc. Securities Litigation, 273 F. Supp. 3d 474 (S.D.N.Y. 2017).

Opinion

[476]*476MEMORANDUM & ORDER

ALISON J. NATHAN, United States District Judge

On June 16, 2016, the Court issued orders approving the plan of allocation of the net settlement fund and the class action settlement. Dkt. Nos. 123-24. The Court now addresses Lead Counsel’s application for attorney’s fees. For the reasons that follow, Counsel’s application is granted in its entirety.

I. Background

The above case is a securities class action brought on behalf of all persons and entities who purchased or acquired the publicly traded common stock of BioScrip, Inc. (“BioScrip”) between November 9, 2012 and November 6, 2013. See Dkt. No. 68, at 1 (hereafter “Mar. 81, 2015 Order”). The consolidated actions stem from allegations that BioScrip violated the securities laws through two sets of allegedly misleading statements: first, statements affirming BioScrip’s compliance with relevant laws notwithstanding the Government’s investigation into an alleged kickback scheme between BioScrip and Novartis Pharmaceuticals Corp.; and second, statements affirming the profitability of BioScrip’s pharmacy benefit management operating segment, notwithstanding the undisclosed loss of a significant segment of that business. See generally Consolidated Class Action Complaint (Dkt. No. 22) (hereafter the “Complaint”). The Court assumes familiarity with the Court’s Memorandum and Order of March 31, 2015, granting in part and denying in part Defendants’ motions to dismiss, which describes in detail the factual and legal contours of the case. See Mar. 31, 2015 Order.

On September 30, 2013, Plaintiff Timothy Faig filed the first class action complaint in this case, Dkt. No. 1, which was followed by the filing of a related complaint on November 15, 2013, by the West Palm Beach Police Pension Fund, 13-cv-8175, Dkt. No. 1. On December 2, 2013, the Fresno County Employees’ Retirement Association (“Fresno” or “Lead Plaintiff’) moved for appointment as lead plaintiff, as well as for approval of its selection of lead counsel, the law firm of Bernstein Litowitz Berger & Grossmann LLP (“BLB & G” or “Lead Counsel”1). Dkt. No. 11. On December 19, 2013, the Court consolidated the two class action complaints, and appointed [477]*477Fresno as Lead Plaintiff and BLB & G as Lead Counsel. Dkt. No. 17.

Lead Counsel represents that, over the next few months, it conducted an extensive factual and legal investigation, pursuant to which counsel reviewed numerous documents, conducted 72 interviews with former employees of BioScrip and other relevant individuals, researched relevant case-law, and consulted with various experts. Ross Decl. ¶ 19. On the basis of this investigation, on February 19, 2014, . Lead Counsel filed Plaintiffs’ Consolidated.Class Action. Complaint, a 110-page document asserting claims under both the Exchange Act of 1934, 15 U.S.C. § 78a et seq., and the Securities Act of 1933,15 U.S.C. § 77a et seq. See Complaint. In particular, Plaintiffs brought five claims against the Defendants: a claim under Section 10(b) of the Exchange Act and Rule 10b-5 promulgated pursuant to that section, a Section 20(a) control person claim, a claim under Section 11 of the Securities Act, a Section 12(a)(2) claim under that act, and a Section 15 control person liability claim. See Mar. 31, 2015 Order at 13. Two sets of Defendants then moved to dismiss the Complaint. See Dkt. Nos. 41, 45. On March 31, 2015, the Court granted in part and denied in part both motions. Mar. 31, 20½ Order. On June 5, 2015, the Court denied the Defendants’ motion for partial reconsideration. Dkt. No. 86. Thereafter, the parties began the discovery process, which included Defendants’ production of approximately 800,000 pages of documents. Ross Decl. ¶ 41.

In August of 2015, the parties agreed to seek a settlement via mediation, and selected former U.S. District Judge Layn Phillips as a mediator. Id. ¶ 42. As part of the mediation process, both parties submitted briefing, and appeared for a full-day mediation session on September 25, 2015. Id. ¶ 46. At the session, the parties debated numerous factual and legal areas of dispute; and ultimately failed to reach an agreement to settle the action. Id. After additional negotiations, however, and after Judge Phillips provided a recommended settlement amount, the parties ultimately reached a resolution, which they submitted to this Court for 'preliminary approval on December 18, 2015. Dkt. No. 101. On February 11, 2016, the Court issued an order preliminarily approving the settlement and providing for notice. Dkt. No. 106.

In the settlement, BioScrip agreed to pay $10,900,000 to settle the lawsuit in its entirety (on behalf of all defendants). 'Ross Decl. ¶ 3; see also Settlement ¶ l(rr) (Dkt. No. 101-1); Dkt. No. 124 (Judgment Approving Class Action Settlement). The settlement agreement also stipulated that Lead Counsel would apply for attorney’s fees, as well as costs and expenses, directly from the fund. See Settlement ¶ 19. The settlement also specified that Defendants would have no responsibility nor liability for attorney’s fees beyond the settlement amount. Id. ¶ 23.

On May 9, 2016, Lead Plaintiff moved to approve the class action settlement and plan of allocation, Dkt. No. 107, and Lead Counsel moved for an award of attorney’s fees, costs, and expenses, Dkt. No. 109. In particular, Lead Counsel requested attorney’s fees in the amount of 25% of the settlement fund, i.e. $2,725,000, plus interest earned at the same rate as the Settlement Fund, reimbursement for $133,565.28 in litigation expenses incurred, and reimbursement to Lead Plaintiff for $1,378.61 in costs. See PI. Mem. at 1; Ross Decl. ¶ 2. Lead Counsel argued that, relying on the percentage method to calculate .a reasonable attorney’s fee, the request should be approved. See id. at 3-4 (citing Goldberger v. Integrated Res., Inc., 209 F.3d 43, 47 (2d Cir. 2000) (contrasting . the percentage method, under which “[tjhe court sets some percentage of the recovery as a fee,” [478]*478with the lodestar -method, “under which the district court scrutinizes the fee petition to ascertain the number of hours reasonably billed to the class and then multiplies that figure by an appropriate hourly rate”)). In this case, Lead .Counsel acknowledged that 25% 'of the. fund would amount to a 1.39 multiplier of Lead Counsel’s lodestar. See PI. Mem. at 9.

On May 23, 2016, the Court received an objection to the fee award, from the Isaac-son/Weaver Family Trust (the “Trust” or “Objector”). See Dkt. No 113 (hereafter “Obj. Mem.”). The Trust objected to any award above the lodestar, primarily on the basis that such án award would be inconsistent with the Supreme Court’s admonition in Perdue v. Kenny A. ex rel. Winn that, when calculating “an attorney’s fee[ ] under federal fee-shifting statutes ... there is a strong presumption that the lodestar is sufficient.” 559 U.S. 542, 546, 130 S.Ct. 1662, 176 L.Ed.2d 494 (2010). No additional objections to the settlement or fee application were received from any class members. See June 13, 2016 Tr. at 4 (Dkt. No. 125).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
273 F. Supp. 3d 474, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-bioscrip-inc-securities-litigation-nysd-2017.